American Cancer Society. Cancer Facts & Figures 2014. Atlanta, Ga: American Cancer Society; 2014.

Benowitz NL. Pharmacology of Smokeless Tobacco Use: Nicotine Addiction and Nicotine-Related Health Consequences. In: Smokeless Tobacco or Health: An International Perspective. Smoking and Tobacco Control Monograph No.2. Bethesda (MD): US Department of Health and Human Services, Public Health Service, National Institutes of Health. NIH Publication No. 93-3461, 1992b:219-228. Accessed at on October 1, 2012. (Content no longer available.)

Benowitz NL. Pharmacologic aspects of cigarette smoking and nicotine addiction. N Engl J Med. 1988;319:1318-1330.

Benowitz NL, Jacob P III, Yu L. Daily use of smokeless tobacco: Systemic effects. Ann Intern Med. 1989;111:112-116.

Boffetta P, Straif K. Use of smokeless tobacco and risk of myocardial infarction and stroke: systematic review with meta-analysis. BMJ. 2009;339.

Caldwell B, Burgess C, Crane J. Randomized crossover trial of the acceptability of snus, nicotine gum, and Zonnic therapy for smoking reduction in heavy smokers. Nicotine Tob Res. 2010;12(2):179-183.

Campaign for Tobacco-free Kids. Health Harms From Smokeless Tobacco Use. June 15, 2012 / Ann Boonn. Accessed at on February 17, 2014.

Cogliano V, Straif K, Baan R, et al. Smokeless tobacco and tobacco-related nitrosamines. Lancet Oncol. 2004;5:708.

Dale LC, Ebbert JO, Glover ED, et al. Bupropion SR for the treatment of smokeless tobacco use. Drug Alcohol Depend. 2007;90:56-63.

Ebbert JO, Croghan IT, North F, Schroeder DR. A pilot study to assess smokeless tobacco use reduction with varenicline. Nicotine Tob Res. 2010;12(10):1037-1040.

Ebbert JO, Croghan IT, Schroeder DR, Hurt RD. A randomized phase II clinical trial of high-dose nicotine patch therapy for smokeless tobacco users. Nicotine Tob Res. 2013;15(12):2037-2044.

Ebbert JO, Dale LC. Treating Spit Tobacco (ST) Dependence: What You Need to Know as a Primary Care Provider. Mayo Clinic Dept Med Intramural Newsl. Accessed at on October 1, 2012. (Content no longer available.)

Ebbert JO, Dale LC, Patten CA, et al. Effect of high-dose nicotine patch therapy on tobacco withdrawal symptoms among smokeless tobacco users. Nicotine Tob Res. 2007;9:43-52.

Ebbert JO, Fagerstrom K. Pharmacological interventions for the treatment of smokeless tobacco use. CNS Drugs. 2012;26(1):1-10.

Ebbert J, Montori VM, Erwin PJ, Stead LF. Interventions for smokeless tobacco use cessation (Review). Cochrane Database Syst Rev. 2011;Issue 2. Art. No.: CD004306.

Fagerström K, Gilljam H, Metcalfe M, Tonstad S, Messig M. Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial. BMJ. 20106;341:c6549.

Fiore MC, Jaén CR, Baker TB, et al, for the Guideline Panel. Treating Tobacco Use and Dependence: 2008 Update. In National Library of Medicine (NLM). Treating Tobacco Use and Dependence: 2008 Update. Accessed at on February 17, 2014. 111th Congress 2009-2010. H.R.1256: Family Smoking Prevention and Tobacco Control Act. Accessed at on February 17,2014.

Hatsukami DK, Grillo M, Boyle R, et al. Treatment of spit tobacco users with transdermal nicotine system and mint snuff. J Consult Clin Psychol. 2000;68(2):241-249.

Hatsukami KD, Gust SW, Keenan RM. Physiologic and subjective changes from smokeless tobacco withdrawal. Clin Pharmacol and Ther. 1987;41:103-107.

Hatsukami DK, Lemmonds C, Zhang Y, et al. Evaluation of carcinogen exposure in people who used “reduced exposure” tobacco products. J Natl Cancer Inst. 2004;96:844-852.

Henley SJ, Connell CJ, Richter P, et al. Tobacco-related disease mortality among men who switched from cigarettes to spit tobacco. Tobacco Control. 2007;16:22-28.

Henley SJ, Thun MJ, Connell C, Calle EE. Two large prospective studies of mortality among men who use snuff or chewing tobacco (United States). Cancer Causes Control. 2005;16:347-358.

Holm H, Jarvis MJ, Russwell MAH, Feyerabend C. Nicotine intake and dependence in Swedish snuff takers. Psychopharmacology. 1992;108:507-511.

Holmén A, Strömberg U, Magnusson K, Twetman S. Tobacco use and caries risk among adolescents--a longitudinal study in Sweden. BMC Oral Health. 2013;13:31. doi: 10.1186/1472-6831-13-31.

Hurt RD, Ebbert JO, Hays JT, McFadden DD. Treating tobacco dependence in a medical setting. CA Cancer J Clin. 2009;59(5):314-326.

IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Smokeless Tobacco and Some Tobacco-specific N-Nitrosamines. Volume 89. World Health Organization International Agency For Research On Cancer. 2007. Accessed at on February 17, 2014.

Jain R, Jhanjee S, Jain V, et al. A double-blind placebo-controlled randomized trial of varenicline for smokeless tobacco dependence in India. Nicotine Tob Res. 2014;16(1):50-57.

Klesges RC, Ebbert JO, Morgan GD, et al. Impact of differing definitions of dual tobacco use: implications for studying dual use and a call for operational definitions. Nicotine Tob Res. 2011;13(7):523-531.

Mushtaq N, Williams MB, Beebe LA. Concurrent use of cigarettes and smokeless tobacco among US males and females. J Environ Public Health. 2012;2012:984561.

National Institute of Dental and Craniofacial Research. Spit Tobacco: A Guide For Quitting. September 2006. Accessed at on February 17, 2014.

Office of the US Surgeon General. 1998 Surgeon General’s Report Tobacco Use Among U.S. Racial/Ethnic Minority Groups. Centers for Disease Control and Prevention (CDC), Office on Smoking and Health. 1998. Accessed at on February 17, 2014.

Office of the US Surgeon General. The Health Consequences of Using Smokeless Tobacco: A Report of the Surgeon General. Centers for Disease Control and Prevention (CDC), Office on Smoking and Health. 1986. Accessed at on February 17, 2014.

Piano MR, Benowitz NL, Fitzgerald GA, et al. Impact of smokeless tobacco products on cardiovascular disease: implications for policy, prevention, and treatment: a policy statement from the American Heart Association. Circulation. 2010;122(15):1520-1544.

Rath JM, Villanti AC, Abrams DB, Vallone DM. Patterns of tobacco use and dual use in US young adults: the missing link between youth prevention and adult cessation. J Environ Public Health. 2012;2012:679134.

Severson HH. Enough Snuff: A Guide for Quitting on Your Own. 6th ed. Eugene, Oregon: Applied Behavior Science Press. 2002.

Severson HH, Klein K, Lichtenstein E, et al. Smokeless tobacco use among professional baseball players: Survey results, 1998 to 2003. Tobacco Control. 2005;14:31-36.

Schiller KR, Luo X, Anderson AJ, et al. Comparing an immediate cessation versus reduction approach to smokeless tobacco cessation. Nicotine Tob Res. 2012;14(8):902-909.

Stepanov I, Biener L, Knezevich A, et al. Monitoring tobacco-specific N-nitrosamines and nicotine in novel Marlboro and Camel smokeless tobacco products: findings from Round 1 of the New Product Watch. Nicotine Tob Res. 2012;14(3):274-281.

Stepanov I, Jensen J, Biener L, et al. Increased pouch sizes and resulting changes in the amounts of nicotine and tobacco-specific N-nitrosamines in single pouches of camel snus and marlboro snus. Nicotine Tob Res. 2012;14(10):1241-1245.

The S.T.O.P. Guide: Smokeless Tobacco Cessation. Applied Behavioral Science Press. 2002.

White AR, Rampes H, Liu JP, Stead LF, Campbell J. Acupuncture and related interventions for smoking cessation. Cochrane Database Syst Rev. 2014;1:CD000009.

Zendehdel K, Nyrén O, Luo J, et al. Risk of gastroesophageal cancer among smokers and users of Scandinavian moist snuff. Int J Cancer. 2008;122(5):1095-1099.

The American Cancer Society medical and editorial content team
Our team is made up of doctors and master’s-prepared nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.

Last Medical Review: February 20, 2014 Last Revised: June 23, 2016